Merck’s 15-valent vaccine candidate was non-inferior to Pfizer’s Prevnar 13 in a Phase III study and provided superior protection against serotype 3, a frequent cause of invasive pneumococcal disease.
Merck & Co., Inc. reported results from two additional Phase III studies of its 15-valent pneumococcal conjugate vaccine V114 on 9 September and revealed that it is sprinting toward the finish line with plans to file for approval, starting with the US Food and Drug Administration, before the end of this year.
That means that Merck & Co. is neck-and-neck with Pfizer Inc. in the race to bring a next-generation pneumococcal...
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.
